Sintilimab: all 353 studies that test it

Page 4 of 4. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.

• Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.Active, not recruitingNCT04220944Phase 1
• Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT04213170Phase 2
• The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal CancerCompletedNCT04212598Phase 2
• Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric CancerStatus unknownNCT04202601Phase 1/2
• Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal CancerStatus unknownNCT04194359Phase 2
• Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLCStatus unknownNCT04189094Phase 2
• Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOSStatus unknownNCT04181489Phase 2
• Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal CancerStatus unknownNCT04179084Phase 2
• A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC PatientsCompletedNCT04177290Phase 1
• Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCCStatus unknownNCT04174781Phase 2
• SinTilimab After Radiation (STAR Study)CompletedNCT04167657Phase 2
• Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)Status unknownNCT04167293Phase 2/3
• Sintilimab in FH-deficient Renal Cell CarcinomaStatus unknownNCT04146831Phase 2
• Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaStatus unknownNCT04140318Phase 2
• Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal TypeActive, not recruitingNCT04127227Phase 2
• Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)Status unknownNCT04124731Phase 2
• SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLCStatus unknownNCT04106180Phase 2
• Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor ThrombosisStatus unknownNCT04104074Phase 1
• Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical CancerStatus unknownNCT04096911Phase 2
• Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy RegimensStatus unknownNCT04089657Phase 2
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant TumorsStatus unknownNCT04085185Phase 1
• Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT04072679Phase 1
• EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)Active, not recruitingNCT04072107Phase 2
• Sintilimab to Prevent High-risk Oral Premalignant Lesions CancerizationStatus unknownNCT04065737Phase 2
• The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.Status unknownNCT04065282Phase 2
• Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide ChemotherapyStatus unknownNCT04056949Phase 2
• Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLCCompletedNCT04055792Phase 2
• Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04052152Phase 2
• A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard ChemotherapyStatus unknownNCT04044222Phase 3
• Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular CarcinomaStatus unknownNCT04042805Phase 2
• Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLCStatus unknownNCT03987867Phase 1
• Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCCCompletedNCT03985046Phase 2
• Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )Status unknownNCT03975270Phase 2
• Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal CancerStatus unknownNCT03946969Phase 2
• A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal CancerStatus unknownNCT03940001Early Phase 1
• Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell LymphomaCompletedNCT03936452Phase 2
• Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC PatientsStatus unknownNCT03874000Phase 2
• HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCCActive, not recruitingNCT03869034Phase 2
• A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.Status unknownNCT03863483Phase 2
• A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing ChemotherapyStatus unknownNCT03830411Phase 2
• Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCLCompletedNCT03820596Phase 1/2
• Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment FailureCompletedNCT03802240Phase 3
• A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.Status unknownNCT03794440Phase 2/3
• Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M NegativeStatus unknownNCT03765775Phase 2
• First in Human Study of IBI101 in Chinese Subjects With Advanced Solid TumorsCompletedNCT03758001Phase 1
• Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )CompletedNCT03748134Phase 3
• Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric CancerCompletedNCT03745170Phase 3
• ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1
• CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer PatientsStatus unknownNCT03732430Phase 2
• Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Phase 3
• PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03619824Phase 2
• Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownNCT03574402Phase 2
• A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.CompletedNCT03545971Phase 1

← Sintilimab overview